Currently approved for sale in more than 50 countries, the Cervidil®/Propess® vaginal insert is the world’s leading cervical ripening product. Cervidil/ Propess has been approved by the FDA, the EMEA and by various other regulatory agencies.
The Company’s robust pipeline of clinical products is primarily focused in the area of women’s health, but does contain compounds that fall outside this specialty.
In addition to its established focus in women’s health, CPSI has a portfolio of early-stage compounds and targets in the areas of inflammation, autoimmune diseases, cancer and HIV.
June 15, 2010
Cytokine PharmaSciences Completes Phase II Study of Controlled Release Misoprostol Vaginal Insert (MVI)
November 30, 2009
Cytokine PharmaSciences Completes Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364
July 20, 2009
Cytokine PharmaSciences Initiates Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364